We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Chromosome Interaction Profiling Reveals Cancer Risk Genes

By LabMedica International staff writers
Posted on 29 Mar 2018
Print article
Image: The HiSeq2000 instrument used for whole-genome sequencing targeted resequencing, gene expression level detection, DNA methylation profiling, de novo sequencing, metagenomic studies, and ChiP-seq (Photo courtesy of Illumina).
Image: The HiSeq2000 instrument used for whole-genome sequencing targeted resequencing, gene expression level detection, DNA methylation profiling, de novo sequencing, metagenomic studies, and ChiP-seq (Photo courtesy of Illumina).
Breast cancer is a heterogeneous disease with two main subtypes defined by the presence (ER+) or absence (ER−) of the estrogen receptor. Approximately 80% of newly diagnosed breast cancers are ER+ although this proportion varies with age at diagnosis and ethnicity.

Genome-wide association studies (GWAS) coupled with large-scale replication and fine-mapping studies have led to the identification of approximately 100 breast cancer risk loci. Potential target and survival-related genes in breast cancer have been identified using chromatin interaction profiles to map parts of the genome previously implicated in risk of the disease.

A team of scientists led by those at the Institute of Cancer Research (London, UK) used a long-range interaction profiling technique called Capture Hi-C (CHi-C) to investigate dozens of regions previously implicated in breast cancer risk. Based on CHi-C data for four breast cancer cell lines with or without enhanced estrogen receptor (ER) activity, a cancer-free breast epithelial cell line, and a cell line from another tissue type, they focused in on 110 potential target genes at 33 of the risk loci.

By adding in related risk single nucleotide polymorphism (SNP) data, RNA sequence profiles, and somatic mutation data reported previously, the team looked at overlap between these proposed targets, expression quantitative trait loci (eQTL), and genes prone to mutation in breast cancer tumors. With the help of gene expression and outcome data from the Metabric breast cancer cohort, meanwhile, the authors highlighted 32 genes with ties to breast cancer survival time. After using HiSeq2000 instruments to sequence target-enriched Hi-C libraries, the team tallied the CHi-C interaction peaks at each risk locus. A dozen risk loci lacked discernable interaction peaks, leaving interaction peaks at 51 loci for further consideration within and across the six cell lines.

The team uncovered potential gene targets at 33 of the breast cancer-associated sites, spanning 94 protein-coding and 16 non-coding RNA gene targets neighboring the risk loci or falling more far afield. They subsequently considered the target genes alongside eQTLs (informed by RNA sequence data from the Cancer Genome Atlas) and somatic mutation profiles identified in hundreds of breast cancer genome sequences, which supported the notion that CHi-C can help unearth authentic target genes.

The authors concluded that a high-throughput CHi-C analysis can contribute to on-going efforts to functionally annotate GWAS risk loci and that CHi-C target genes that are supported by additional data sources are strong candidates for in-depth functional follow-up studies. The study was published on March 12, 2018, in the journal Nature Communications.

Related Links:
Institute of Cancer Research

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.